Columbia Labs Advantage-S Additional HIV Prevention Trials Unlikely

"It will be very difficult to conduct another study" on Advantage-S (nonoxynol-9) and HIV prevention after a Joint U.N. Program on HIV/AIDS trial produced negative results, Columbia Labs Chairman and CEO William Bologna asserted during a June 12 conference call.